Chemoprevention of Gastric Cancer: Metformin.
10.7704/kjhugr.2017.17.4.179
- Author:
Young Il KIM
1
;
Soo Jeong CHO
Author Information
1. Center for Gastric Cancer, National Cancer Center, Goyang, Korea. crystal522@ncc.re.kr
- Publication Type:Review
- Keywords:
Chemoprevention;
Metformin;
Stomach neoplasms
- MeSH:
Chemoprevention*;
Epidemiologic Studies;
Humans;
Metformin*;
Stomach Neoplasms*
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2017;17(4):179-184
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Metformin is a first-line anti-diabetic drug that has been widely used in patients with type 2 diabetes. Many population-based epidemiologic studies have shown that metformin treatment is associated with decreased risk for various cancers. Recent epidemiologic studies showed that the use of metformin was associated with a reduction in gastric cancer risk, especially in patients with type 2 diabetes who used metformin for long periods of time (>2~3 years). Currently, there are no registered clinical trials investigating the anti-cancer effect of metformin in gastric cancer; hence, further well-designed clinical trials are required. Herein, we review the literature regarding the use of metformin for the prevention of gastric cancer.
